TXMD · TherapeuticsMD, Inc.
$2.01
+0.01 (+0.50%)
At close · Oct 8
View the 10-Q filed Aug 11, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$23.15M
Shares
11.57M
Volume · Oct 8
13.81K
Avg daily vol (3M)
23.83K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.01
Open$2.00
Day$1.99–2.03
52W close$1.04–2.77
Avg vol 30d20K
Short int26K · 0.2% float · 1.3d
Short vol29%
Last earningsNov 14, 2022
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
call held Aug 15, 2022
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$3.27M
Trailing 12 months
Net income (TTM)
−$217,000
Trailing 12 months
Revenue growth YoY
-8.7%
Year over year
Operating margin
-120.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.6%
Year over year · more shares
Price change (1Y)
+92.4%
Trailing year
Short interest
0.2%
Latest settlement · 1.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
−5%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
56%
mid-range
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−3%
trailing
YTD return
+23%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
1 of 47 funds reported for Sep 30 · net -9 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.23% of float · ▲ +0.2% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
47 holders — mid 3-yr range
Squeeze score
37
low risk · 0–100
Fundamentals
Revenue growth
+35%
Y/Y
Gross margin
74%
contracting
EPS growth
+74%
Y/Y
Free cash flow
$-142.7M
Balance sheet
$123.4M
net debt
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
3.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 6, 2020
Cash expenses (opex, excluding noncash items)
· back half of the year
$80M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−5%
Neutral
Price vs 50-day avg
−5%
Neutral
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
56%
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
1 of 47 funds reported for Sep 30 · net -9 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.23% of float · ▲ +0.2% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
47 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 56%
Range high $3
vs 200-day avg -5%
vs 50-day avg -5%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TXMD
this stock
TherapeuticsMD, Inc.
|
$23.15M | +23.3% | +35.3% | — | 0.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.68B | +18.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$45.83B | -5.0% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.66B | +25.8% | +4.3% | 64.2 | 2.7% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$41.48B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TXMD | -1.0% | -4.3% | -2.9% | -1.0% | +23.3% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -2.3% | -6.4% | -11.9% | -2.5% | +9.8% |